MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END
/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...
MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics...
Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...
Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program ...
/PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns...
Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee...
Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022 Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for...
Company Highlights Factually Accurate Information Already Provided Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors –...